In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2887-2890

  Gunderson, S M ^a   Hoffman, H ^a   Ernst, E J ^a   Pfaller, M A ^a   Klepser, M E ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; NYSTATIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FUNGICIDAL ACTIVITY; FUNGUS IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL;

ANTIBIOTICS, ANTIFUNGAL; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; MICROBIAL SENSITIVITY TESTS; NYSTATIN;

EID: 0033802638     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2887-2890.2000     Document Type: Article

References (12)

1. A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis
2. The in vitro post-antifungal effect of nystatin on Candida species of oral origin
3. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
4. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: Effect of concentration and exposure time
5. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
6. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
7. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods
8. Evaluation of voriconazole pharmacodynamics using time-kill methodology
9. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
10. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic
11. The postantibiotic effect of antifungal agents against common pathogenic yeasts